Publication: FCERI and Histamine Metabolism Gene Variability in Selective Responders to NSAIDS.
dc.contributor.author | Amo, Gemma | |
dc.contributor.author | Cornejo-Garcia, Jose A | |
dc.contributor.author | Garcia-Menaya, Jesus M | |
dc.contributor.author | Cordobes, Concepcion | |
dc.contributor.author | Torres, M J | |
dc.contributor.author | Esguevillas, Gara | |
dc.contributor.author | Mayorga, Cristobalina | |
dc.contributor.author | Martinez, Carmen | |
dc.contributor.author | Blanca-Lopez, Natalia | |
dc.contributor.author | Canto, Gabriela | |
dc.contributor.author | Ramos, Alfonso | |
dc.contributor.author | Blanca, Miguel | |
dc.contributor.author | Agundez, Jose A G | |
dc.contributor.author | Garcia-Martin, Elena | |
dc.contributor.authoraffiliation | [Amo,G; Esguevillas,G; Martínez,C; Agúndez,JAG; García-Martín,E] Departamento de Farmacología, Universidad de Extremadura, Cáceres, Spain. [Cornejo,JA; Mayorga,C] Laboratorio de Investigación, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain. [García-Menaya,JM; Cordobes,C] Servicio de Alergologia, Hospital Infanta Cristina, Badajoz, Spain. [Torres,MJ] UGC de Alergia, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain. [Blanca-Lopez,N; Canto,G; Blanca,M] Servicio de Alergologia, Hospital Infanta Leonor, Madrid, Spain. [Ramos,A] Departamento de Matemáticas, Universidad de Extremadura, Cáceres, Spain. | es |
dc.contributor.funder | FEDER funds from the European Union | |
dc.contributor.funder | Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain | |
dc.contributor.funder | Junta de Extremadura, Spain | |
dc.date.accessioned | 2016-11-11T09:18:24Z | |
dc.date.available | 2016-11-11T09:18:24Z | |
dc.date.issued | 2016-09-29 | |
dc.description.abstract | The high-affinity IgE receptor (Fcε RI) is a heterotetramer of three subunits: Fcε RIα, Fcε RIβ, and Fcε RIγ (αβγ2) encoded by three genes designated as FCER1A, FCER1B (MS4A2), and FCER1G, respectively. Recent evidence points to FCERI gene variability as a relevant factor in the risk of developing allergic diseases. Because Fcε RI plays a key role in the events downstream of the triggering factors in immunological response, we hypothesized that FCERI gene variants might be related with the risk of, or with the clinical response to, selective (IgE mediated) non-steroidal anti-inflammatory (NSAID) hypersensitivity. From a cohort of 314 patients suffering from selective hypersensitivity to metamizole, ibuprofen, diclofenac, paracetamol, acetylsalicylic acid (ASA), propifenazone, naproxen, ketoprofen, dexketoprofen, etofenamate, aceclofenac, etoricoxib, dexibuprofen, indomethacin, oxyphenylbutazone, or piroxicam, and 585 unrelated healthy controls that tolerated these NSAIDs, we analyzed the putative effects of the FCERI SNPs FCER1A rs2494262, rs2427837, and rs2251746; FCER1B rs1441586, rs569108, and rs512555; FCER1G rs11587213, rs2070901, and rs11421. Furthermore, in order to identify additional genetic markers which might be associated with the risk of developing selective NSAID hypersensitivity, or which may modify the putative association of FCERI gene variations with risk, we analyzed polymorphisms known to affect histamine synthesis or metabolism, such as rs17740607, rs2073440, rs1801105, rs2052129, rs10156191, rs1049742, and rs1049793 in the HDC, HNMT, and DAO genes. No major genetic associations with risk or with clinical presentation, and no gene-gene interactions, or gene-phenotype interactions (including age, gender, IgE concentration, antecedents of atopy, culprit drug, or clinical presentation) were identified in patients. However, logistic regression analyses indicated that the presence of antecedents of atopy and the DAO SNP rs2052129 (GG) were strongly related (P < 0.001 and P = 0.005, respectively) with selective hypersensitivity to ibuprofen. With regard to patients with selective hypersensitivity to ASA, men were more prone to develop such a reaction than women (P = 0.011), and the detrimental DAO SNP rs10156191 in homozygosity increased the risk of developing such hypersensitivity (P = 0.039). | es |
dc.description.sponsorship | This study was financed by grants PI12/00241, PI12/00324, PI15/00303, RETICS RD12/0013/0002, and RETICS RD16/0006/0004 from Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain, and GR15026 from Junta de Extremadura, Spain. Financed in part with FEDER funds from the European Union. | |
dc.description.version | Yes | es |
dc.identifier.citation | Amo G, Cornejo-García JA, García-Menaya JM, Cordobes C, Torres MJ, Esguevillas G, et al. FCERI and Histamine Metabolism Gene Variability in Selective Responders to NSAIDS. Front Pharmacol. 2016; 7:353 | es |
dc.identifier.doi | 10.3389/fphar.2016.00353 | |
dc.identifier.essn | 1663-9812 | |
dc.identifier.pmc | PMC5040715 | |
dc.identifier.pmid | 27746735 | |
dc.identifier.uri | http://hdl.handle.net/10668/2511 | |
dc.journal.title | Frontiers in Pharmacology | |
dc.language.iso | en | |
dc.page.number | 9 | |
dc.provenance | Realizada la curación de contenido 02/04/2025 | |
dc.publisher | Frontiers Research Foundation | es |
dc.relation.projectID | PI12/00241 | |
dc.relation.projectID | PI12/00324 | |
dc.relation.projectID | PI15/00303 | |
dc.relation.projectID | RD12/0013/0002 | |
dc.relation.projectID | RD16/0006/0004 | |
dc.relation.projectID | GR15026 | |
dc.relation.publisherversion | http://journal.frontiersin.org/article/10.3389/fphar.2016.00353/full#h1 | es |
dc.rights | Attribution 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Fcε | es |
dc.subject | RI | es |
dc.subject | Histamine | es |
dc.subject | Non-steroidal anti-inflammatory drugs (NSAIDS) | es |
dc.subject | Hypersensitivity drug reactions | es |
dc.subject | Biomarkers | es |
dc.subject | Acetaminofén | es |
dc.subject | Antiinflamatorios no Esteroideos | es |
dc.subject | Aspirina | es |
dc.subject | Diclofenaco | es |
dc.subject | Dipirona | es |
dc.subject | Ácido flufenámico | es |
dc.subject | Marcadores genéticos | es |
dc.subject.decs | Histamina | |
dc.subject.decs | Ibuprofeno | |
dc.subject.decs | Inmunoglobulina E | |
dc.subject.decs | Indometacina | |
dc.subject.decs | Cetoprofeno | |
dc.subject.decs | Piroxicam | |
dc.subject.decs | Polimorfismo de Nucleótido Simple | |
dc.subject.decs | Piridinas | |
dc.subject.decs | Receptores de IgE | |
dc.subject.decs | Sulfonas | |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amides::Anilides::Acetanilides::Acetaminophen | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Peripheral Nervous System Agents::Sensory System Agents::Analgesics::Analgesics, Non-Narcotic::Anti-Inflammatory Agents, Non-Steroidal | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Carbocyclic::Benzoic Acids::Hydroxybenzoic Acids::Salicylic Acids::Aspirin | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Carbocyclic::Phenylacetates::Diclofenac | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Pyrazoles::Pyrazolones::Aminopyrine::Dipyrone | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Carbocyclic::Benzoic Acids::Aminobenzoic Acids::Anthranilic Acids::Fenamates::Flufenamic Acid | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Biological Factors::Biological Markers::Genetic Markers | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amines::Biogenic Amines::Biogenic Monoamines::Histamine | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Carbocyclic::Phenylpropionates::Ibuprofen | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Immunoglobulin Isotypes::Immunoglobulin E | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 2-Ring::Indoles::Indomethacin | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Carbocyclic::Phenylpropionates::Ketoprofen | es |
dc.subject.mesh | Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models, Statistical::Logistic Models | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Polycyclic Hydrocarbons, Aromatic::Naphthalenes::Naphthaleneacetic Acids::Naproxen | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Pyrazoles::Pyrazolones::Phenylbutazone::Oxyphenbutazone | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Sulfur Compounds::Thiazines::Piroxicam | es |
dc.subject.mesh | Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic::Polymorphism, Single Nucleotide | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyridines | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Fc::Receptors, IgE | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Sulfur Compounds | es |
dc.title | FCERI and Histamine Metabolism Gene Variability in Selective Responders to NSAIDS. | es |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- AmoG_FCERIAndHistamineMetabolism.pdf
- Size:
- 427.44 KB
- Format:
- Adobe Portable Document Format
- Description:
- Artículo publicado